Insider Selling: Glaukos (NYSE:GKOS) Director Sells 5,000 Shares of Stock

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 5,000 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total value of $536,350.00. Following the transaction, the director directly owned 34,905 shares of the company’s stock, valued at approximately $3,744,259.35. This trade represents a 12.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Glaukos Stock Performance

Shares of GKOS traded up $0.61 during mid-day trading on Thursday, hitting $109.33. The stock had a trading volume of 776,580 shares, compared to its average volume of 985,589. The firm has a market cap of $6.28 billion, a P/E ratio of -70.99 and a beta of 0.69. The business has a fifty day moving average price of $90.84 and a 200-day moving average price of $92.58. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $163.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The company had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. During the same quarter in the prior year, the company earned ($0.28) EPS. The firm’s quarterly revenue was up 38.1% compared to the same quarter last year. On average, equities research analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Institutional Trading of Glaukos

Several institutional investors and hedge funds have recently bought and sold shares of the company. UMB Bank n.a. grew its position in shares of Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 158 shares in the last quarter. REAP Financial Group LLC bought a new stake in Glaukos during the third quarter valued at $40,000. Park Place Capital Corp grew its position in Glaukos by 68.4% during the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 162 shares in the last quarter. AlphaQuest LLC grew its position in Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 633 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its stake in Glaukos by 42.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock worth $98,000 after acquiring an additional 362 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GKOS. Stifel Nicolaus set a $115.00 target price on shares of Glaukos in a research note on Monday, October 27th. Wells Fargo & Company raised their price objective on shares of Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. JPMorgan Chase & Co. boosted their target price on shares of Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. UBS Group restated a “buy” rating and set a $140.00 target price on shares of Glaukos in a research report on Monday, November 10th. Finally, Citigroup lifted their price target on Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $120.62.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.